VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Gilead Sciences, Inc. vs VeriSign, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisVeriSign, Inc.
VRSN · Nasdaq Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into VeriSign, Inc.'s moat claims, evidence, and risks.
View VRSN analysisComparison highlights
- Moat score gap: VeriSign, Inc. leads (100 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); VeriSign, Inc. has 1 segment (100% in Naming Services (.com and .net registry)).
- Primary market structure: Oligopoly vs Monopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; VeriSign, Inc. has 4 across 4.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
VeriSign, Inc.
Naming Services (.com and .net registry)
Registry operator services for .com and .net top-level domains (domain registrations + authoritative DNS resolution)
Global
ICANN-accredited domain registrars (wholesale) and, indirectly, registrants
Registry operator / DNS infrastructure provider
100%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Gilead Sciences, Inc. strengths
VeriSign, Inc. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
VeriSign, Inc. segments
Full profile >Naming Services (.com and .net registry)
Monopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.